---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010615"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T11:16:53.049415+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics reports Q4 2022 net loss $11.8M, full year loss $41.0M; cash $99.3M

## Summary
- Net loss for Q4 2022 was $11.8M and full year 2022 was $41.0M.
- R&D expenses for full year 2022 were $29.5M vs $16.9M in 2021; G&A $12.8M vs $4.7M.
- Cash, cash equivalents and investments totaled $99.3M at Dec 31, 2022, expected to fund through mid-2024.
- Phase 2/3 pivotal trial for epetraborole in MAC lung disease approaching 60 sites; Phase 2 enrollment expected to complete mid-2023.
- Awarded up to $17.8M NIAID contract to develop epetraborole for melioidosis using non-dilutive funding.

## SEC filing metadata
- accession: 0000950170-23-010615
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017023010615/0000950170-23-010615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017023010615/antx-20230329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010615
- JSON: https://secwatch.observer/filing/0000950170-23-010615.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010615.txt

## Key facts
- Earnings Releases
  AN2 Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income net loss was $11.8 million and $41.0 million, respectively.
  - Period: the fourth quarter and year ended December 31, 2022
  - Net income: net loss was $11.8 million and $41.0 million, respectively
  - Result: reported results
  source text: AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000095017023010615/0000950170-23-010615-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.